Collaboration Arrangements - Additional Information (Detail) - USD ($)					1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 30, 2016	Nov. 09, 2016	Feb. 10, 2016	Jan. 04, 2016	Jan. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Sep. 23, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								$ 62,000	$ 161,781,000	$ 187,000	$ 161,781,000
Secured loan facility, amount borrowed										19,429,000
Paid-in-kind interest											4,125,000
Gain on extinguishment of debt										(830,000)
Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration						$ 10,200,000
Sanofi-Aventis Deutschland GmbH | Put Option
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payment for insulin put option					$ 30,600,000							$ 30,600,000
Aventisub LLC
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Outstanding loan balance forgiven		$ 72,000,000
Receptor
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration								100,000		200,000
Nonrefundable payments										400,000
Nonrefundable option exercise and license fee	$ 1,000,000
Reduction in research and development expense										400,000
Deferred revenue - nonrefundable license fee								1,000,000		$ 1,000,000
Deferred revenue recognition period										4 years
License and Collaboration Agreement with Sanofi
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Profits and losses sharing percentage										35.00%
Termination date				Apr. 04, 2016
Maximum secured loan facility														$ 175,000,000
Senior notes, effective interest rate														8.50%
Gain on extinguishment of debt		$ 500,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										$ 172,000,000
Deferred revenue - nonrefundable license fee								150,000,000		$ 150,000,000
Profits and losses sharing percentage										65.00%
Milestone receivable								$ 25,000,000		$ 25,000,000
Deferred cost													$ 13,500,000
Secured loan facility, amount borrowed			$ 17,900,000										44,500,000
Secured loan facility, amount owed							$ 71,200,000		$ 71,200,000		$ 71,200,000
Paid-in-kind interest							$ 5,800,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										17,500,000
Deferred revenue - nonrefundable license fee													17,500,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Up Front Payment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										150,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment One
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										25,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Milestone Payment Two
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										25,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										19,400,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenue from collaboration										$ (64,900,000)
Company's total portion of loss sharing													$ 57,700,000